Background: Abnormalities of cardiac structure and function are common in a wide
A c c e p t e d M a n u s c r i p t
ntroduction
The oldest old are the fastest growing population segment in New Zealand but have been under-represented in previous studies describing the prevalence and prognostic importance of abnormalities of cardiac structure and function. [1, 2] Abnormalities of cardiac structure and function occur in a wide range of populations including those with and without established clinical cardiovascular disease (CVD).
One of the most common adaptations is left ventricular hypertrophy (LVH) which is also a well-recognised marker of adverse outcome in populations with and without hypertension and coronary artery disease. [3, 4] LVH can be further subdivided into different geometric patterns using the relative wall thickness (RWT), which may be a better measure of LVH since it takes into account the overall size and wall thickness of the left ventricle. [5] Using this methodology, for those with LVH, two geometric patterns are defined: concentric hypertrophy (CH) and eccentric hypertrophy (EH). Those without LVH can be further categorised into normal geometry (NG) and concentric remodelling (CR), i.e. increased relative wall thickness without increase in LV mass. Concentric remodelling has been associated with adverse outcome in patients with hypertension [6] and importantly a reversal of the concentric remodelling pattern to NG has been associated with improved clinical outcome. [7] Understanding the prevalence of abnormalities of cardiac structure and function, and its implication among people of advanced age is important, as it cannot be assumed that similar prevalence and prognostic importance of such abnormalities will apply to this population as they do for younger populations. The aims of this study were to determine the prevalence of LVH and the four patterns of LV geometry among A c c e p t e d M a n u s c r i p t 5 people of advanced age and establish the clinical characteristics and five-year outcomes (all-cause mortality, CVD events and hospital admissions) of each group.
Methods
This study was initiated as part of the feasibility study [8] leading to the Life and Living to Advanced Age, a cohort study in New Zealand (LiLACS NZ). [9] The study was initiated in January 2008 and data on hospital admission and mortality were collected 
Measures
Socio-demographic, smoking status, use of prescribed medications and medical history were ascertained through a face-to-face interview. Physical assessments (height, weight and blood pressure) were completed by trained research nurses using standardised procedures. Fasting blood samples were collected and analysed for serum glucose, lipids and NT-proBNP. Echocardiography was performed by an experienced echocardiographer using a portable echocardiography machine (Sonosite MicroMaxx, Fuji Sonosite, Bothell, WA) according to the recommendations of the American Society of Echocardiography. [5] Images were recorded in digital format for offline analysis. Clinically manifest CVD was established by self-report CVD and from review of nationally held hospitalisation records. [8] Outcomes were ascertained through review of the nationally held mortality and hospitalisation records including and up to five years after initial assessment. Type 2 diabetes mellitus was ascertained from selfreported diabetes, records of glucose-lowering medications from the questionnaire, fasting serum glucose >7.0mmol/L, [11] or hospitalisation records of diabetes.
Hypertension was defined as self-reported hypertension, records of prescribed 
Statistical Analysis
Socio-demographic data are presented as frequencies and percentages. Continuous data was examined with histogram and box-plots, and are presented as mean and standard deviations (SD), or medians and interquartile ranges (IQR) for variables with a skewed distributions. ANOVA and Kruskal-Wallis with Scheffe's post hoc test were used for comparisons among multiple groups. A listwise deletion approach was adopted. Cox's proportional hazard regression analysis was used to determine the association between LV geometry and five-year all-cause mortality and logistic regression models for association between LV geometry and CVD events and hospital admissions adjusting for age, sex and variables found to be different across the four LV geometry groups. A p value <0.05 was considered statistically significant.
Statistical analyses were performed with SPSS 18.0 for Windows.
Results

Sample
A total of 186 eligible older adults were invited to participate of which 112 were 
Demographics and Medical History
In this sample, 33 were Māori and 79 non-Māori. Forty-eight (56%) were women, half were widowed, and 38% were married/de facto. Most of the participants lived in a private residence (86%) and three-quarters had received secondary (38%) or tertiary (36%) education.
Half of the study participants (n=55) had never smoked tobacco cigarettes. Ninetytwo (85%) participants had dyslipidaemia, 91 (84%) had a history of hypertension, 22
(20%) had type 2 diabetes, 72 (67%) had CVD, and 69 (64%) were receiving BPlowering medication.
LV Structure
Sixteen (16%) echocardiograms were done in the participants' residences, of which three were found to been technically very limited due to poor echocardiographic views. Eighty-four (84%) echoes were performed in a local health centre, of which 10 were found to have technically difficult views. All echoes (n=100) were included in the analysis.
M a n u s c r i p t respectively, p=0.051 (Figure 1 ).
When LVM was indexed to BSA, similar trends between those with and without LVH were observed as above, except for NT-proBNP levels which were statistically higher among those with LVH than without LVH, median (IQR) 61pmol/L (74) vs. 34pmol/L (38.5) (p=0.023), and the proportion of use of vitamin/mineral supplements between those with and without LVH became not statistically significant (39% vs. 57% vs.
LV Geometry
Forty participants displayed normal geometry (NG), 12 concentric remodelling (CR), 10 concentric hypertrophy (CH) and 22 eccentric hypertrophy (EH) (Figure 1 and Table 1 ). 
LVH, LV Geometry, Mortality and Morbidity
Over five years, 41 (37%) participants died, 27 participants had at least one CVD event (five new and 22 recurrent), and the number of all cause hospital admissions ranged between 0 and 23 admissions, median (IQR) was 2 (4); 45 (42%) participants had three or more hospital admissions. 
Discussion
The results from this study of cardiac structure among people of the oldest old demonstrated that approximately half had normal LV geometry, more than one-third had LVH (between 33% and 38% depending on method of indexation) and LV systolic dysfunction was only seen among 5% of elderly people whereas most had a history of hypertension (84%) and two-thirds a history of CVD. When present, LVH was associated with larger left atrial size and (marginally) higher NT-proBNP levels and higher mortality compared with those without LVH. In nonagenarians, NTproBNP levels have been observed to be higher and associated with LVH. [14] 
LV Hypertrophy in Advanced Age
LVH is well-recognised as a marker of adverse outcome in populations with and without hypertension and coronary artery disease. [3, 4] The prevalence of LVH has been reported from a large number of studies including many different populations and the current data are consistent with the prevalence rates of LVH observed from 
LV Geometry in Advanced Age
Normal LV Geometry
The current data demonstrate that half of this sample of the oldest old has normal LV geometry. The definition of LV geometry depends on the definition of LV hypertrophy used, which depends on the method of indexation (allometric indexation to a power of height or to body surface area), and in turn the cut-off used to define hypertrophy.
While debate continues regarding the optimal method for indexation of LV measurements we have followed those currently recommended in contemporary guidelines. [5] A recent study of 106 nonagenarians and centenarians in a residential home in Italy reported that only 16% of their population had normal LV geometry. [17] The current study used similar echocardiographic methods and LVH definitions to the Italian study. Both the Italian and our study cannot determine the relative time exposure to risk factors (e.g. diabetes, hypertension, and BP-lowering medications) associated with development of LVH and abnormal LV geometry. The time course of further progression across the worsening patterns of LV geometry clearly also cannot be determined. It is not unreasonable to speculate that the normal geometry may be related to optimal management of hypertension.
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Concentric remodelling is of relevance as this geometric pattern of increased wall thickness but without LVH has been shown to be associated with adverse outcome among patients with hypertension. [6, 18, 19] In clinically healthy adults, ageing has been associated with the development of LV concentric remodelling, although these data are based on only small numbers of older people over the age of 65 years. [20] A more recent study, utilising an echocardiographic database and including only patients over 70 years of age (mean age 78 years), demonstrated that CR was the commonest geometrical pattern, seen among 43% of this population, with a further 16% having LVH. The study found higher RWT and LV mass were predictors of total mortality independent of age, BMI and gender. [21] Compared to normal LV geometry, CR is a significant independent predictor of CV events in middle-age adults with mild hypertension. [22] In a study involving adults with an average age of 62 years without clinical CVD, CR was predictive of stroke and coronary heart disease over a four-year follow-up period. [23] Our current data demonstrate that CR was present in 14% of the sample and characteristics of this group were similar to those with normal LV geometry at baseline. However, CR conferred a higher risk of death from any cause and hospitalisation compared to those with normal geometry. These findings confirm people of advanced age with CR have an adverse prognosis as observed in younger population. [6, 7] 
LV Geometry and LV Diastolic Function
Abnormalities of LV diastolic filling are commonly associated with LVH and increased LV mass is a predictor of the development of heart failure. [23] The current data demonstrate that markers of LV diastolic function (LA area and E/e') were abnormal among those with LVH compared with those without LVH, and in particular the participants with EH had highest E/e'. This is in line with the population-based participants aged 35-74 years, which found that participants with CH and EH had higher LV filling pressure (assessed using E/e') than those with NG. [24] In the LIFE (Losartan Intervention For Endpoint reduction hypertension) Study, patients with hypertension (mean age 67 years) with increased LV mass had abnormal LV diastolic function.
[25] Although our study found LV diastolic dysfunction was related to LVH, LV diastolic function was not related to all-cause mortality, CVD events and adverse clinical outcomes resulting in hospitalisation, whereas the type of remodelling was, perhaps suggesting that the LV shape and size is more important in predicting outcome than the diastolic filling pattern.
Limitations
The study is limited by the small sample size but is valuable because of the five-year 
Conclusion
This study has demonstrated that despite a high prevalence of CVD and hypertension, half of the sample had normal LV geometry, CR was present in 14%
and approximately one in three had LVH. LV geometry predicts five-year all-cause mortality and was associated with CVD events and adverse clinical outcomes.
Findings from this study extend the limited data already available on LV geometry in M a n u s c r i p t A c c e p t e d M a n u s c r i p t M a n u s c r i p t Figure 1 Cumulative survival plot on a) LVH, and b) 4 LV geometry M a n u s c r i p t -The numbers in each LV geometry group were smaller compared to the baseline data as not all participants gave consent to follow-up data -CVD event is defined as CVD related hospital admission A c c e p t e d M a n u s c r i p t 
